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Abdominal aortic aneurysms (AAAs) and heart failure
are complex life-threatening diseases whose etiology
is not completely understood. In this study, we inves-
tigated whether deficiency of group V secretory phos-
pholipase A2 (GV sPLA2) protects from experimental
AAA. The impact of GV sPLA2 deficiency on angioten-
sin (Ang) II–induced cardiac fibrosis was also investi-
gated. Apolipoprotein E (apoE)/mice and apoE/
mice lacking GV sPLA2 (GV DKO) were infused with
1000 ng/kg per minute Ang II for up to 28 days. In-
creases in systolic blood pressure, plasma aldoste-
rone level, and urinary and heart prostanoids were
similar in apoE/ and GV DKO mice after Ang II
infusion. The incidence of aortic rupture in Ang II–
infused GV DKOmice (10%) was significantly reduced
compared with apoE/ mice (29.4%). Although the
incidence of AAA in GV DKO mice (81.3%) and
apoE/ mice (100%) was similar, the mean percent-
age increase in maximal luminal diameter of abdom-
inal aortas was significantly smaller in GV DKO mice
(68.5%  7.7%) compared with apoE/ mice
(92.6%  8.3%). Deficiency of GV sPLA2 resulted in
increased Ang II–induced cardiac fibrosis that was most
pronounced in perivascular regions. Perivascular colla-
gen, visualized by picrosirius red staining, was associ-
ated with increased TUNEL staining and increased im-
munopositivity for macrophages and myofibroblasts
and nicotinamide adenine dinucleotide phosphate oxi-
1088dase (NOX)-2 and NOX-4, respectively. Our findings in-
dicate that GV sPLA2 modulates pathological responses
to Ang II, with different outcomes for AAA and cardiac
fibrosis. (Am J Pathol 2012, 181:1088–1098; http://dx.doi.
org/10.1016/j.ajpath.2012.05.037)
Cardiovascular diseases are the number one killer world-
wide (World Health Organization, http://www.who.int/
mediacenter/factsheets/fs310/en/index.html, updated June
2011, last accessed June 19, 2012), and a role for the
renin-angiotensin-aldosterone system as a contributor to
cardiovascular disease is clear.1–3 Inhibition of the renin-
angiotensin-aldosterone system with either angiotensin-
converting enzyme inhibitors or angiotensin (Ang) II re-
ceptor blockers is effective in reducing cardiovascular
morbidity and mortality in humans.1,4 Furthermore, the
beneficial effects of Ang II receptor blockers in the treat-
ment of congestive heart failure and myocardial fibrosis
have been demonstrated in both animal models and hu-
man trials.1,4,5 Recent studies suggest that, in addition to
its action as a potent vasoconstrictor, Ang II directly
mediates pathological responses in the heart and vascu-
lature, including endothelial activation and reactive oxy-
gen species (ROS) generation, through activation of the
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pathways underlying these effects are not fully under-
stood.
We recently reported that deficiency of group X secre-
tory phospholipase A2 (GX sPLA2) ameliorates abdomi-
nal aortic aneurysm (AAA) formation in Ang II–infused
apolipoprotein E (apoE)/ mice.7 AAA is recognized as
an inflammatory disorder characterized by localized ex-
tracellular matrix degradation, leading to dilation of the
abdominal aorta. Aortic rupture due to AAA is a major
cause of mortality in men aged 65 to 85 years,8 and
therapeutic interventions that have been proved to pre-
vent AAA progression and aortic rupture in humans are
not available. Aneurysms produced in apoE/ mice that
are chronically infused with Ang II exhibit many features
of human AAA, including medial degeneration, inflamma-
tion, thrombus formation, and rupture of the abdominal
aorta.9 Thus, the Ang II infusion model has been widely
used as a relevant model for mechanistic studies of AAA.
The decreased incidence of AAA in apoE/ mice defi-
cient in GX sPLA2 (GX DKO mice) was associated with
decreased aortic expression of several genes implicated
in AAA, including matrix metalloproteinase-2, IL-6, and
cyclooxygenase-2 (COX-2). Furthermore, analysis by
gelatin zymography demonstrated that both the latent
and active forms of matrix metalloproteinase-2 were de-
creased in abdominal aortas of Ang II–infused GX DKO
mice compared with apoE/ mice.7 These findings sug-
gest that GX sPLA2 promotes Ang II–induced pathologi-
cal responses, leading to AAA formation in this animal
model. Notably, we also reported that GX sPLA2 is pres-
ent in human aneurysmal tissue, suggesting that this
enzyme may contribute to human AAA.7
GX sPLA2 is one member of a family of 10 isozymes
that catalyze the hydrolysis of the sn-2 ester of glycero-
phospholipids to produce free fatty acids and lysophos-
pholipids. Determining the biological functions of specific
sPLA2s is challenging, given the relatively large number
of family members, their overlapping tissue distribution,
and their distinct phospholipid substrate specificity. Nu-
merous important biological and pathological functions,
such as host immunity and inflammation,10,11 atheroscle-
rosis,12,13 apoptosis,14–16 and ROS generation,15,17 have
been mediated or enhanced by sPLA2s. One mechanism
by which sPLA2s are thought to exert their biological
effects is through the generation of free fatty acids and
lysophospholipids that have pleiotropic effects on cell
function. By liberating arachidonic acid, sPLA2s hold the
potential to produce a wide variety of bioactive lipid me-
diators, including prostaglandins, thromboxanes, leuko-
trienes, and lipoxins. In vitro studies using artificial phos-
pholipid substrates indicate that group V (GV) and GX
sPLA2s are the most potent in hydrolyzing phosphatidyl-
choline, the major phospholipid on mammalian cell mem-
branes. However, the extent to which these two enzymes
perform redundant functions in vivo is not clear. In this
study, we investigated whether deficiency of GV sPLA2,
such as GX, protects apoE/ mice from Ang II–induced
AAA. We also investigated whether either GX or GV
sPLA2 deficiency modulates the development of cardiac
fibrosis that occurs in Ang II–infused mice.18Materials and Methods
Experimental Animals
Male C57BL/6 and apoE-/ mice backcrossed 10 times
on a C57BL/6 background were originally obtained from
the Jackson Laboratory (Bar Harbor, ME). GV sPLA2-
deficient mice, also backcrossed 10 times with
C57BL/6 mice, were a gift from Jonathan Arm (Harvard
Medical School, Brigham and Women’s Hospital, Boston,
MA).19 GV sPLA2
/ mice were crossed with apoE/
mice to obtain GV sPLA2
/  apoE/ (GV DKO) mice.
All mice were housed in microisolator cages with a nor-
mal rodent diet and water provided ad libitum. Ang II
(1000 ng/kg per minute; Sigma, St. Louis, MO) or saline
was administered s.c. into male mice (aged 8 to 10
weeks) at 3, 7, 10, or 28 days, as indicated in the figure
legends, via Alzet osmotic minipumps (model 2004;
Sigma) using established techniques.20 Where indicated,
losartan (25 mg/kg per day) was delivered, along with
Ang II, via osmotic minipumps, as previously de-
scribed.21 Studies were performed with the approval of
the University of Kentucky, Lexington, Institutional Animal
Care and Use Committee.
Blood Pressure Measurements
Mean systolic blood pressure levels were measured in
conscious mice using a computerized tail-cuff method
(BP-2000; Visitech Systems Inc., Apex, NC). Mice were
acclimatized to the system for 1 week before the initiation
of studies, and systolic blood pressure was measured 5
days per week until study termination.
Quantification of AAAs
AAAs were assessed in anesthetized mice by high-fre-
quency ultrasonography using a Vevo 660 high-resolu-
tion system (VisualSonics Inc., Toronto, ON, Canada).
Maximal luminal diameters of suprarenal abdominal aor-
tas were determined 1 day before the initiation of Ang II
infusion and 1 day before study termination. Necropsy
was performed on all animals that died during the Ang II
infusion, and macroscopic photographs were taken of
the abdominal cavities. All of the animals that died before
study termination succumbed within the first 7 days after
pump implantation because of aortic rupture.
Histological Analyses of Heart Sections
Hearts were collected from PBS-perfused mice, fixed in
10% formaldehyde, and embedded in paraffin. Cross
sections (5 m thick) were collected at the level of the
papillary muscles and stained with picrosirius red, as
previously described.22 Collagen deposition was visual-
ized under polarized light as red birefringent fluores-
cence and quantified by two independent investigators in
a blinded manner using ImagePro software. Apoptosis
was detected using a commercially available kit for the
TUNEL assay (Roche Diagnostics Operations Inc., Indi-
anapolis, IN). Collagen was also visualized using Gomori
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Bouin solution for 1 hour at 56°C, washed in distilled H2O,
counterstained in Weigert hematoxylin for 10 minutes at
room temperature, washed again, and incubated in Go-
mori stain for 20 minutes at room temperature. Frozen
sections from AAA were subjected to immunohistochem-
istry (IHC) using chicken anti-mouse GV,13 GX sPLA2
antibodies (10 g/mL), or rabbit anti-macrophage serum
(Accurate Chemical and Scientific Corp, Westbury, NY)
in 1:1000 dilution. IHC staining was also performed on
paraffin-embedded sections of mouse hearts using rat
anti-mouse CD68 antibody for macrophages and rabbit
anti-mouse -actin antibody for smooth muscle cells
(SMCs) and myofibroblasts, along with biotinylated goat
anti-rat or goat anti-rabbit secondary antibodies, respec-
tively. Samples were visualized with the ABC system
(Vector Laboratories, Inc., Burlingame, CA) and AEC (3-
amino-9-ethylcarbazole) as chromogen.
RNA Isolation and Quantitative RT-PCR
Abdominal aortas, defined as the part of the vessel be-
tween the diaphragm and the aortic bifurcation, were
cleaned of adhering fat tissues, placed in RNAlater (Am-
bion, Valencia, CA), and then homogenized in RNeasy
Fibrous Mini Kit solution (Qiagen). The heart tissues were
homogenized, and the RNA was extracted by the TRIzol
method (Sigma). For real-time RT-PCR, 0.2 to 0.5 g of
RNA was reverse transcribed using the Reverse Tran-
scription System (Promega, Madison, WI). Real-time RT-
PCR was performed using Power SYBR Green Master
Mix (Applied Biosystems, University Park, IL) on a DNA
iQ5 Multicolor Real-time PCR Detection system (Life
Technologies, Grand Island, NY). Quantification was per-
formed using the standard curve method and normalized
with 18S. Sequences of PCR primers are available on
request.
Indirect Immunofluorescence
Hearts were collected from PBS-perfused mice, fixed in
10% formaldehyde, and embedded in paraffin. Cross
sections (5 m thick) cut at the level of the papillary
muscles were mounted on slides. Paraffin was removed
by two washes in xylene. Samples were rehydrated in
decreasing concentrations of ethanol (100%, 95%, and
70%) and then washed two times with PBS. Antigen re-
trieval was performed by gentle heating in 10 mmol/L
citrate. Samples were blocked for 1 hour at room temper-
ature with PBS containing 1.5% normal goat or rabbit
serum. Sections were then incubated for 1 hour at room
temperature with a combination of primary antibodies, as
indicated. The primary antibodies were chicken anti-
mouse GV sPLA2 IgG (10 g/mL)
13 and rabbit anti-
smooth muscle -actin IgG (1:100; Abcam, Cambridge,
MA) for visualization of vascular SMCs and myofibro-
blasts. After four washes with 0.2% Tween-20 in PBS, GV
sPLA2 was detected using Alexa Fluor 568–labeled goat
anti-chicken IgG (1:200; Molecular Probes, Cambridge,
MA). Vascular SMCs were detected using Alexa Fluor
488–labeled goat anti-rabbit IgG (1:200; MolecularProbes). NOX-2 and NOX-4 were detected using rabbit
antibodies (Abcam) and Alexa Fluor 568–labeled goat
anti-rabbit IgG (1:200; Molecular Probes). Slides were
mounted using fluorescence-protecting medium contain-
ing DAPI (Vectashield; Vector Laboratories). Confocal
microscopy was performed using an Olympus laser-
scanning microscope with UV, argon (488-nm), and kryp-
ton (568-nm) lasers.
Aldosterone Quantification
Aldosterone was measured in plasma using a commercially
available kit (Diagnostic Systems Labs, Webster, TX).
Quantification of Prostanoid Metabolites
Mice were individually housed for 24 hours in metabolic
cages for collection of urine. Lipids were extracted from
urine using acidified organic solvents with addition of
internal recovery standard. Lipids were extracted from
heart tissue after homogenization, using acidified organic
solvents with addition of internal recovery standard.23
Liquid chromatography–tandem mass spectrometry ana-
lyses of eicosanoids were performed using an ABI 4000-
Qtrap hybrid linear ion-trap triple-quadruple mass spec-
trometer (International Equipment Trading Ltd, Vernon
Hills, IL) in multiple reaction monitoring mode. Eico-
sanoids were separated using a Zorbax Eclipse XDB C8
column (5 m thick, 4.6 150 mm) (Agilent, Santa Clara,
CA). The mobile phase consisted of 63:39:0.5 v/v/v water/
acetonitrile/formic acid as solvent A and 50:50 v/v ace-
tonitrile/iso-propaqnol as solvent B. For the analysis of
eicosanoids, the separation was achieved using a linear
gradient of 0% to 100% solvent B in 6 minutes, main-
tained at 100% solvent B for the next 4 minutes, and
equilibrated back to the initial conditions in 3 minutes.
The flow rate was 0.3 mL/minute, with a column temper-
ature of 30°C. The sample injection volume was 10 L.
The mass spectrometer was operated in the negative
electrospray ionization mode, with optimal ion source
settings determined by synthetic standards with a de-
clustering potential of 35 V, an entrance potential of
10 V, a collision energy of 18 V, a collision cell exit
potential of 7 V, curtain gas of 30 psi, ion-spray voltage
of 4500 V, ion source gas of 40 psi, and temperature of
550°C. Multiple reaction monitoring transitions were as
follows: dextro (d)6-tetranor prostaglandin E2 metabolite,
mass/charge ratio (m/z) 333.5/314.6, 333.5/296.6; tetra-
nor prostaglandin E2 metabolite, m/z 327.5/308.6, 327.5/
290.6; d4-prostaglandin D2 (PGD2), m/z 355.7/318.8,
355.7/236.8; PGD2, m/z 351.7/314.7, 351.7/232.5; d4-
thromboxane B2, m/z 373.7/172.8, 373.7/198.7; thrombox-
ane B2, m/z 369.7/168.7, 369.7/194.7; d4-6-keto prosta-
glandin F1, m/z 373.7/166.7, 373.7/248.8; and 6-keto-
prostaglandin F1, m/z 369.7/162.8, 369.7/244.7. Liquid
chromatography–tandem mass spectrometry calibrations
were obtained with R2  0.998, except for tetranor prosta-
glandin E2 metabolite R
2  0.996.
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For comparison of two groups on a continuous response
variable, a two-sample Student’s t-test was used. A one-
way analysis of variance, followed by Tukey’s multiple com-
parison test, was used to compare more than two groups.
The percentage incidence of AAAs was analyzed by Fish-
er’s exact test. P  0.05 was considered to be statistically
significant. All data were represented as mean  SE.
Results
GV sPLA2 Deficiency Modulated Ang II–Induced
AAA in ApoE/ Mice
We recently reported that GX sPLA2 deficiency signifi-
cantly reduced the incidence of Ang II–induced AAA in
apoE/ mice.7 We also determined that GX sPLA2 was
present in AAA of Ang II–infused apoE/ mice, most
prominently in regions containing macrophages.7 By us-
ing an isoform-specific antibody, we demonstrated that
GV sPLA2 was also present in AAA of Ang II–infused
apoE/ mice; as expected, GV sPLA2 was not detected
in AAA of GV DKO mice (see Supplemental Figure S1 at
http://ajp.amjpathol.org). GV sPLA2 appeared to be more
diffusely distributed in AAA compared with what we pre-
viously described for GX sPLA2,
7 although staining was
evident in regions immunopositive for the macrophage
marker CD68 (see Supplemental Figure S2 at http://
ajp.amjpathol.org).
To investigate whether GV sPLA2 contributed to exper-
imental AAA, we assessed AAA formation in apoE/ and
GV DKO mice infused with Ang II for 7, 10, or 28 days
(1000 ng/kg per minute). During these studies, some of
the mice died during the first 7 days of Ang II infusion
because of aortic rupture (see Supplemental Figure S3 at
http://ajp.amjpathol.org). This early event was attributed
to initial effects of Ang II that led to medial disruption and
aortic wall weakening.24 Interestingly, aortic rupture dur-
ing the first 7 days of Ang II infusion was significantly less
prevalent in GV DKO mice (10% incidence) compared
with apoE/ mice (29.4% incidence; Figure 1A), indicat-
ing that GV sPLA2 contributed to the processes leading
to aortic rupture. AAA progression was assessed in all
surviving animals by determining the maximal luminal
diameters of abdominal aortas before and after Ang II
infusion by in vivo ultrasonography. For both strains of
mice, Ang II infusion resulted in an increase in luminal
diameter that advanced with longer durations of infusion
(Figure 1B). However, at each time point, the expansion
of abdominal aortas in GV DKO mice was less pro-
nounced compared with apoE/ mice, with the differ-
ence reaching statistical significance in mice infused for
10 or 28 days (Figure 1, B and C; see also Supplemental
Figure S4 at http://ajp.amjpathol.org). Although the overall
expansion of the abdominal aorta was reduced in GV
DKOmice, the total number of mice that either developed
an aneurysm (defined as a 50% increase in the maxi-
mal diameter of the abdominal aorta lumen) or died from
aortic rupture during the 28-day Ang II infusion was notsignificantly different in apoE/ mice (100%) compared
with GV DKO mice (81.25%). We interpreted our data to
suggest that GV sPLA deficiency did not influence the
Figure 1. A: Rupture rate in apoE/ and GV sPLA2
/  apoE/ (GV DKO)
mice during the first 7 days of Ang II infusion. The number of animals that had
an aortic rupture and the total number of animals in five separate experiments
are indicated (two experiments were terminated at 7 days, one experiment was
terminated at 10 days, and two experiments were terminated at 28 days). B:
Mean SEM percentage increase in maximal luminal diameter of the abdominal
aorta compared with baseline after the indicated duration of Ang II infusion. C:
Representative images showing the lumens of abdominal aortas of mice infused
with saline or Ang II for 28 days. *P  0.05 versus apoE/ mice.2
incidence of Ang II–induced AAA, but might have alleviated
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and a decreased expansion of the abdominal aorta.
We reported that the decreased incidence of AAA in
GX DKO mice was associated with an altered inflamma-
tory response to Ang II, as evidenced by significantly
reduced induction of specific matrix metalloproteinases
and inflammatory mediators in aortas of GX DKO mice
compared with apoE/ mice after 10-day Ang II infu-
sion.7 Similar to findings in GX DKOmice, the induction of
IL-6 was significantly blunted in aortas of GV DKO mice
compared with apoE/ mice after a 10-day Ang II infu-
sion (see Supplemental Figure S5 at http://ajp.amjpathol.
org). However, in contrast to GX DKO mice, Ang II–
induced increases in the abundance of F4/80, COX-2,
and matrix metalloproteinase-2 mRNAs were not signifi-
cantly reduced in GV DKO mice compared with apoE/
mice (see Supplemental Figure S5 at http://ajp.amjpathol.
org). Interestingly, basal expression of COX-2 in GV DKO
mice was significantly lower compared with apoE/
mice, perhaps reflecting the known cross talk between
COX-2 and GV sPLA2.
25,26 Taken together, our data in-
dicated that GV sPLA2 augmented Ang II–induced in-
flammatory responses and AAA formation in apoE/
mice, although to a lesser extent than we previously re-
ported for GX sPLA2.
7
GV sPLA2 Deficiency Increases Ang II–Induced
Heart Fibrosis in ApoE/ Mice
GV sPLA2 was expressed in the human
27 and mouse28
heart, where it was implicated in the pathogenesis of
myocardial ischemia-reperfusion injury.29 Thus, it was of
interest to determine whether deficiency of this enzyme
modulated Ang II–induced cardiac injury, leading to
heart fibrosis. Accordingly, heart sections were prepared
from apoE/ and GV DKO mice infused with either sa-
line or Ang II for 7 or 28 days and stained with picrosirius
red to visualize collagen fibrils. Somewhat surprisingly,
Ang II–infused GV DKO mice exhibited a significant in-
crease in collagen deposition compared with Ang II–
infused apoE/ mice that was evident in interstitial ar-
eas, but most prominent in perivascular regions of both
the right and left ventricles (Figure 2, A and B; see also
Supplemental Figure S6A at http://ajp.amjpathol.org). The
enhanced fibrotic response in Ang II–infused GV DKO
mice was not associated with a significant difference in
the extent of cardiac hypertrophy (Figure 2C). The in-
crease in collagen deposition was associated with 11-
fold higher collagen I mRNA expression in hearts of GV
DKO mice compared with apoE/ mice after 7 days of
Ang II infusion, a difference that was not statistically sig-
nificantly different because of large variability in the GV
DKO mice (see Supplemental Figure S6B at http://ajp.
amjpathol.org).
To investigate whether the fibrotic response in Ang
II–infused GV DKO mice required angiotensin receptor
subtype 1a (AT1aR) signaling, the mice were co-infused
with losartan (25 mg/kg per day), along with Ang II for 7
days. As previously published,21 losartan prevented the
development of Ang II–induced AAAs (data not shown).Losartan also significantly reduced cardiac fibrosis in
Ang II–infused GV DKO mice, demonstrating that the
AT1aR signaling pathway was necessary for the patho-
genic effect observed in these mice (Figure 2D). On the
other hand, hyperlipidemia did not appear to play a role
in this pathological characteristic because the profibrotic
effect was also observed in C57BL/6 mice lacking GV
sPLA2 (see Supplemental Figure S7 at http://ajp.amjpathol.
org). Studies in GX DKO mice indicated that, unlike GV
sPLA2, GX sPLA2 did not protect the heart from Ang
II–induced cardiac fibrosis (see Supplemental Figure S8
at http://ajp.amjpathol.org).
GV sPLA2 Is Up-Regulated in Hearts of
Ang II–Infused ApoE/ Mice
We performed real-time RT-PCR and IHC staining to as-
sess whether Ang II altered the expression of GV sPLA2
in apoE/ mouse hearts. Our data indicated a trend for
increased GV sPLA2 mRNA abundance after 3 days of
Ang II infusion, but this difference did not reach statistical
significance (Figure 3A). Because it was possible that GV
sPLA2 expression was selectively increased only in cer-
tain cell types, we performed immunofluorescence anal-
ysis to assess GV sPLA2 expression in the heart after 7
days of Ang II infusion. GV sPLA2 was detected in car-
diomyocytes in control apoE/ hearts, consistent with
previous reports that this isozyme was localized to
cardiomyocytes in human hearts, after myocardial in-
farction,30 and BALB/c mouse hearts.28 The intensity of
Figure 2. Collagen content in hearts of apoE/ and GV DKO mice
infused with Ang II for 28 days. A: Picrosirius red staining of representa-
tive heart sections visualized under light microscopy (top panels) and
polarized light microscopy (bottom panels). The images are composed
from four individual pictures. Original magnification, 4. B: Collagen
quantification is performed under polarized light using ImagePro soft-
ware (n  6 to 8). *P  0.05 versus Ang II–infused apoE/ mice. C:
Heart/body ratio. *P  0.05 versus corresponding saline-infused mice.
n.s., not significant. D: Collagen content is quantified as in B in hearts
from GV DKO mice infused for 7 days with saline, Ang II, or Ang II plus
losartan (Lo; n  4 to 6). *P  0.05 versus saline-infused mice; †P  0.05
versus mice infused with Ang II alone.staining was not dramatically altered in cardiomyo-
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tected positive immunostaining for GV sPLA2 that co-
localized with factor VIII, an endothelial marker, in
control and Ang II–infused hearts. However, this stain-
ing was sporadic, probably because of loss of endo-
thelial cells during the processing of the slides (data
not shown). Notably, GV sPLA2–immunopositive stain-
ing also colocalized with vascular SMCs in apoE/
mouse hearts and appeared to be more pronounced
after 7-day Ang II infusion (Figure 3B). As expected,
GV sPLA2 was not detected in hearts of GV DKO mice
Figure 3. Expression of GV sPLA2 in saline and Ang II–infused apoE
/
mouse hearts. A: Real-time RT-PCR showing increased mRNA abundance in
apoE/ hearts after 3 days of Ang II infusion. B: IHC analysis of heart
sections from an apoE/ mouse infused with saline or Ang II for 7 days. GV
sPLA2 (red fluorescence) and SMC -actin (green fluorescence) are visualized
by confocal microscopy. Arrows indicate smooth muscle cells, and aster-
isks indicate cardyomyocytes. Original magnification, 40. C: GV sPLA2 is
not detected in the GV DKO mouse heart.(Figure 3C).Ang II Infusion Resulted in Severe Perivascular
Fibrosis, Apoptosis, and Macrophage Infiltration
in the Myocardium of GV DKO Mice
Results from picrosirius red staining indicated extensive
collagen deposition in the perivascular region of GV DKO
hearts in response to long-term Ang II infusion. This find-
ing was substantiated by additional histological exami-
nation of hearts stained with Gomori trichrome, which
revealed the presence of many mononuclear cells (Fig-
ure 4A: the region of congregated mononuclear cells is
evident on the high-magnification image), a damaged
intimal layer (Figure 4A), and extensive connective tissue
deposition in the region surrounding the vessel wall in GV
DKO animals that was not observed in apoE/ mice.
TUNEL staining revealed an abundance of apoptotic nuclei
in the myocardium of Ang II–infused GV DKOmice that was
not apparent in apoE/ mice (Figure 4B). In addition, IHC
staining revealed the presence of myofibroblasts and mac-
rophages in the perivascular regions of Ang II–infused
hearts that was particularly evident in GV DKOmice (Figure
5). Taken together, these data suggested that GV sPLA2
protected the heart from Ang II–induced damage to the
vessel wall and neighboring myocardium.
Figure 4. A: Gomori trichrome staining of representative heart sections from
apoE/ and GV DKO mice infused with saline or Ang II, showing perivas-
cular damage in Ang II–infused mice that is most pronounced in GV DKO
mice. The box in the bottom middle panel indicates a region shown at
higher magnification in the bottom right panel. Arrow indicates damaged
endothelium. B: TUNEL staining (green fluorescence) showing multiple
apoptotic nuclei surrounding vessels of an Ang II–infused GV DKO mouse.
Original magnification, 40.
1094 Boyanovsky et al
AJP September 2012, Vol. 181, No. 3GV sPLA2 Deficiency Does Not Result in
General Hypersensitivity to Ang II Infusion
To exclude the possibility that the enhanced fibrotic re-
sponse in GV DKO mice was due to an overall hyperre-
sponsiveness to Ang II, we measured blood pressures
and plasma aldosterone levels in apoE/ and GV DKO
mice infused with saline or Ang II (1000 ng/kg per minute)
for 28 days. These analyses showed that systemic renin-
angiotensin-aldosterone system activation in response to
Ang II infusion, as assessed by elevated systolic blood
pressure and plasma aldosterone levels, was similar for
the two strains (see Supplemental Figure S9, A and B, at
http://ajp.amjpathol.org). In addition, the effect of Ang II
infusion to augment whole body prostanoid synthesis,31
as reflected by 24-hour urinary excretion of the major
metabolites of prostaglandin E2 (PGE2), prostacyclin
(PGI2), PGD2, and thromboxane A2 (TxA2) measured 7
days after initiation of Ang II infusion, was not altered in
GV DKO mice (see Supplemental Figure S9, C–F, at
http://ajp.amjpathol.org). Furthermore, analysis of heart
tissue from apoE/ and GV DKO mice indicated that
both PGI2 and PGE2 metabolites, but not TxA2 or PGI2
metabolites, were significantly increased after Ang II in-
fusion, and GV sPLA2 deficiency did not alter these in-
creases (Figure 6). Taken together, our data indicated
that GV sPLA2 deficiency did not result in a generally
altered response to Ang II.
Increased NOX-2 and NOX-4 Immunostaining Is
Detected in Ang II–Infused GV DKO Hearts in
Regions of Perivascular Fibrosis
Considerable evidence suggested that NADPH-depen-
dent production of ROS plays a key role in Ang II–medi-
ated cardiovascular pathological conditions.32,33 Most
studies pointed to NOX-2 as the major isoform responsi-
ble for heart hypertrophy, endothelial dysfunction, and
Figure 5. IHC of mouse hearts infused with Ang II for 7 days. The SMCs/
myofibroblasts (A and C) and macrophages (B and D) in apoE/ (A and B)
and GV DKO (C and D) mice, respectively, visualized by immunostaining
using anti--actin or anti-CD68 antibodies. Original magnification, 20.apoptosis.33–37 Another study, however, reported thatNADPH oxidase activity was elevated in NOX-2/ mice
after aortic banding, which was attributed to increased
NOX-4 expression.38 To investigate the possibility that
GV sPLA2 reduced oxidative stress in the heart vascula-
ture, NOX-2 and NOX-4 expression was assessed by IHC
in hearts of apoE/ and GV DKO mice after 7-day saline
or Ang II infusion. NOX-2 in the myocardium of both
apoE/ and GV DKO mice infused with saline was de-
tected at low levels (Figure 7), and NOX-4 was not de-
tected (data not shown). Interestingly, both NOX-2 and
NOX-4 immunostaining appeared to be markedly in-
creased in the hearts of Ang II–infused GV DKO mice
compared with apoE/ mice in regions of perivascular
fibrosis (Figure 7).
Discussion
In this study, we report the novel finding that GV sPLA2
modulates the vascular remodeling that occurs in mice in
response to long-term Ang II infusion. By using apoE/
mice with targeted disruption of GV sPLA2 (GV DKO
mice), we determined the following: i) GV sPLA2 contrib-
utes to the progression of Ang II–induced AAA, as evi-
denced by a reduced incidence of aortic rupture and
decreased expansion of the abdominal aorta in GV DKO
mice compared with apoE/ mice; and ii) GV sPLA2
protects mice from cardiac fibrosis, particularly perivas-
cular fibrosis induced by Ang II. The finding that GV
sPLA2 deficiency protects mice from Ang II–induced AAA
is consistent with the previous report that the nonselec-
tive sPLA2 inhibitor, varespladib, significantly reduces
AAA in this same animal model.39 The effect of varesp-
ladib on the development of Ang II–induced heart fibrosis
has not been addressed. A possible explanation that
could account for the beneficial effect of GV sPLA2 defi-
ciency toward AAA development, while having a detri-
mental effect on heart fibrosis, is that, in both cases, there
is an effect on tissue remodeling that has opposite out-
comes for the two pathological conditions. Our findings
highlight that the physiological/pathophysiological con-
sequence of GV sPLA2 activity may be multidirectional,
potentially influenced by the tissue where it is expressed
and the context driving its expression. The importance of
our study relates to the development of sPLA2 inhibitors
Figure 6. Prostanoid metabolites 6-keto-PGF1, (prostacyclin metabolite,
A) and; PGEM (PGE metabolite, B) in hearts from mice after 7-day saline or
Ang II infusion measured by reversed-phase electrospray ionization tandem
mass spectrometry (n  8 to 10). No significant differences are detected
/between apoE and GV DKO mice within a treatment group. *P  0.05
versus saline-infused mice.
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beneficial.
We recently reported that deficiency of a related en-
zyme, GX sPLA2, reduces the incidence of AAA in Ang
II–infused apoE/ mice by approximately 50%.7
Whether GV and GX sPLA2 contribute to AAA formation
through common mechanism(s) remains to be deter-
mined. It is possible that these enzymes play redundant
functions in the abdominal aorta, and that deficiency of
both GV and GX sPLA2 would completely abolish Ang
II–induced AAA. The finding that the induction of IL-6 is
blunted in GV DKO mice, as we reported previously for
GX DKOmice,7 is consistent with other evidence that IL-6
is a key mediator of AAA.41 An association between se-
rum sPLA2 activity and the presence of aneurysm, but not
progression, has been reported.42 However, serum
sPLA2 activity most likely reflects GIIA sPLA2 activity,
43
whereas GV and GX sPLA2 are thought to exert localized
actions. Thus, a role for GV or GX sPLA2 as a serummarker
for aneurysm progression seems unlikely. Whether sys-
temic GIIA sPLA2 contributes to Ang II–induced AAA in
mice merits another study.
In contrast to its beneficial effect on AAA, deficiency of
GV sPLA2 resulted in significantly increased cardiac fi-
brosis that was evident in mice infused with Ang II for 7 or
28 days. Although there was evidence of interstitial col-
lagen deposition in Ang II–infused GV DKO mice, the
most pronounced fibrosis localized to perivascular re-
gions. This fibrotic effect occurred in the absence of any
alteration in the hypertensive response to Ang II. No-
tably, studies in C57BL/6 mice indicated that defi-
ciency of GV sPLA2 leads to increased Ang II–induced
cardiac fibrosis, even in the absence of hyperlipid-
emia. Interestingly, the extent of cardiac fibrosis was
not significantly altered in Ang II–infused GX DKO mice
compared with the control strain, despite a pro-
nounced effect, as previously noted, of GX sPLA2 to
augment Ang II–induced AAA.7
Increased collagen deposition in hearts of Ang II–in-
fused GV DKO mice was significantly reduced by losar-
Figure 7. NOX-2 and NOX-4 expression in hearts of apoE/ and GV DKO
mice infused with saline or Ang II for 7 days, as indicated. Hearts isolated
from apoE/ and GV DKOmice are subjected to immunofluorescence using
anti-NOX-2 or NOX-4 antibodies and visualized under confocal microscopy
using red fluorescence–labeled secondary IgGs. Original magnification,60.tan administration, pointing to AT1aR signaling in thefibrotic effect. There is substantial evidence implicating
Ang II in cardiac fibrosis,44 and several studies in hu-
mans have suggested that angiotensin-converting en-
zyme inhibitors or AT1aR antagonists are effective in pre-
venting secondary cardiovascular events and chronic
heart failure.31 Whether these beneficial outcomes are
attributable to reductions in blood pressure or other pleio-
tropic effects of Ang II has been difficult to determine.
Accumulating evidence indicates that Ang II acts as a
circulating vasoconstrictor affecting blood pressure and
as a paracrine and autocrine hormone to locally induce
cell growth, oxidative stress, and inflammation, leading to
tissue damage and, ultimately, cardiac hypertrophy, fi-
brosis, and heart failure.3 The recent development of
genetically modified mouse strains has provided insights
differentiating the local effects of Ang II from its hemody-
namic functions. For example, transgenic mice with car-
diac-specific overexpression of Ang II have 10- to 15-fold
higher Ang II expression in cardiac tissue compared with
nontransgenic littermates, whereas plasma Ang II levels
and systolic blood pressure are similar.45 Under basal
conditions, these mice develop mild cardiac fibrosis with-
out cardiac hypertrophy.45 More recently, Xu et al46 de-
veloped a mouse model with low circulating renin–Ang II
and high cardiac-specific Ang II expression and demon-
strated that Ang II in the context of hypertension acts
locally via AT1aR to increase macrophage infiltration, ox-
idative stress, apoptosis, and fibrosis in the heart. In
another study, transgenic knock-in mice expressing a
constitutively active AT1aR exhibited early and progres-
sive cardiac fibrosis without cardiomyocyte hypertrophy
or inflammation.47 The fibrosis, which was predominantly
perivascular, was associated with only mild hypertension.
Although these mouse models point to a direct action of
Ang II via the AT1aR in regulating fibrotic responses in the
heart, additional studies are needed to precisely define
how AT1aR activation leads to fibrosis. Our findings sug-
gest that GV sPLA2 may counteract AT1aR-dependent
pathways leading to cardiac remodeling through a mech-
anism that appears to be independent of the hemody-
namic effects of Ang II, a conclusion that is supported by
the fact that both ventricles were affected as a result of
GV sPLA2 deficiency (data not shown).
GV sPLA2 mRNA is expressed at high levels in the
human heart,48 and GV sPLA2 protein has been associ-
ated with ischemic cardiomyocytes during the acute
phase of infarction, supporting the concept that GV
sPLA2 plays a role in cardiac remodeling in humans.
30 In
mice, deficiency of GV sPLA2 reduces myocardial injury
and echocardiographic left ventricular dysfunction af-
ter ischemia-reperfusion.29 The pathological effect of
GV sPLA2 in myocardial ischemia-reperfusion injury
was attributed to the coordinated action of GV sPLA2,
along with activated cPLA2, to amplify the local pro-
duction of leukotriene B4 and thromboxane A2.
29 Al-
though the previous study indicated that GV sPLA2, in
conjunction with cPLA2, plays a causative role in acute
myocardial ischemia-reperfusion injury, our results
suggest that GV sPLA2 plays a cardioprotective role in
the setting of long-term Ang II infusion. Although fibro-
sis may develop as a direct consequence of cardiomy-
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trigger chronic cardiomyocyte damage and gradual
fibrous tissue deposition are also common. The mech-
anisms underlying cardiac remodeling in these two
scenarios may be distinct, with GV sPLA2 activity hav-
ing seemingly divergent consequences.
Numerous studies have documented the ability of GV
sPLA2 to generate arachidonic acid as a substrate for
eicosanoid biosynthesis.10,19,49–51 The eicosanoid profile
present in tissues orchestrates the inflammatory re-
sponse to acute and chronic injury and varies substan-
tially in different cell types and on different inflammatory
stimuli, depending on the combination of prostanoid
and leukotriene synthases that are expressed at the
site of injury.52 With inflammation, both the amount and
the profile of eicosanoids produced by cells may be
altered dramatically. For example, although propor-
tionally more TxA2 is produced by resting macro-
phages compared with PGE2, this ratio changes when
the cells are activated by lipopolysaccharide stimula-
tion.53 Locally generated eicosanoids can either pro-
mote or restrain inflammation, depending on the pres-
ence of a diverse range of cellular receptors that are
coupled to intracellular signaling pathways regulating
divergent effects on cell function. Interestingly, the
same bioactive mediator may contribute both to the
initiation and resolution of inflammation, depending on
the context.54 Ang II enhances systemic biosynthesis
of prostaglandins in mice, as reflected by increased
urinary secretion of the major PGE2, PGD2, PGI2, and
TxA2 metabolites
31 (see Supplemental Figure S9, C–F,
at http://ajp.amjpathol.org). Evidence suggests that
modulation of the prostanoid profile can affect both the
development and extent of Ang II–induced AAA.3,31,55
Arachidonic acid metabolites have also been linked to
cardiac fibrosis associated with inflammation, with
PGE2 generally thought to augment and PGI2 thought
to attenuate fibrotic responses.35,36 It is tempting to
speculate that, in the setting of Ang II infusion, the
absence of GV sPLA2 tips the heart to a more fibrotic
eicosanoid profile, an effect that may be manifested in
a localized and transient manner. We were unable to
detect significant differences in the eicosanoid content
of hearts from Ang II–infused apoE/ and GV DKO
mice, perhaps because of insufficient sensitivity to de-
tect changes confined to small regions of the heart or
restricted to certain cell types.
A striking finding from our study was the marked in-
duction of NOX-2 and NOX-4 that colocalized with areas
of collagen deposition in GV DKO hearts. A major mech-
anism by which Ang II exerts its detrimental effects in the
heart is through NADPH-driven generation of ROS. Nu-
merous studies have shown that the primary source of
ROS in the heart is NADPH oxidase, with NOX-2 and
NOX-4, but not NOX-1, being the main isoforms respon-
sible.33 In addition to stimulating ROS formation and in-
creasing oxidase activity, Ang II also up-regulates the
expression of NADPH oxidase subunits.32 The impor-
tance of NOX-2 in Ang II–induced cardiac fibrosis has
been demonstrated in NOX-2–null mice, which have sig-
nificantly reduced NF-B activation, NADPH oxidase ac-tivity, interstitial fibrosis, and expression of fibronectin
and procollagen I mRNA, compared with wild-type mice,
in response to Ang II infusion.37
Aldosterone may have a direct role in cardiac re-
modeling independent of sodium retention.46 This hy-
pothesis is supported by reports that low-dose spi-
ronolactone has clear beneficial effects in patients with
heart failure who are independent of alterations in
blood pressure or fluid retention.54 Whether GV sPLA2
modulates the response to Ang II by altering aldosterone-
mediated effects merits further investigation. Another poten-
tial mechanism underlying our findingsmay relate to the fact
that GV sPLA2-deficient macrophages show impaired
phagocytosis.56 Thus, the observed accumulation of mac-
rophages and TUNEL-positive cells around the vessel wall
might be the result of defective clearance of dead cells,
leading to increased expression of inflammatory markers
and ROS generation. Defining the mechanisms underlying
GV sPLA2-mediated protection against heart fibrosis may
provide novel therapeutic approaches for treating human
fibrotic diseases.
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